Exscientia plc

NasdaqGM:EXAI Stok Raporu

Piyasa değeri: US$633.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Exscientia Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Exscientia'in gelirinin artacağı tahmin edilmektedir.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi23.4%
Gelir büyüme oranı39.8%
Gelecekteki özkaynak getirisi-15.12%
Analist kapsamı

Low

Son güncelleme21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Nov 12

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Exscientia plc ( NASDAQ:EXAI ) just released its latest third-quarter results and things are looking bullish. Revenue...

Recent updates

Seeking Alpha • Aug 08

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Summary Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered value for shareholders since their big-money IPOs, with share prices down by >75%. Both companies have proprietary drugs in their pipeline and programs in which they partner with Big Pharma companies to accelerate drug development. AI hype aside, this is a surprisingly underperforming sector of the stock market, with these types of companies struggling to develop strong pipelines or attract Pharma partners despite a high cash burn. As such, this deal's main strength is creating a larger company that can be more dominant within the industry. With that said, there are potentially valuable accretive data readouts later this year and early next for Recursion's rare disease candidates. Read the full article on Seeking Alpha
Analiz Makalesi • Jul 17

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 10

Exscientia: Too Much Pessimism

Summary Exscientia is using AI to improve drug discovery and address the low returns on investments in the pharmaceutical industry. While preclinical data generally looks promising, it is too early to know the overall impact of AI on drug discovery. While there is significant risk, Exscientia's low enterprise value and relatively integrated approach to AI-enabled drug discovery potentially provide an opportunity. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Exscientia: Drug Discovery Platform Attracting Partners And Cash

Summary Exscientia plc's stock has underperformed the biotechnology and IT sectors, despite owning a tech platform attracting big pharma. The company uses AI to accelerate drug development and reduce time to market, potentially improving success rates. The partnerships with major pharmaceutical companies are generating cash inflows and the potential for future royalties. The company differentiates itself using its tech platform, which also uses LLMs (large language models) and Generative (Gen) AI. It is trading at about half its February 2023 peak as the AI hype has deflated but remains vulnerable to interest rate-related risks if the Federal Reserve adopts a hawkish tone. Read the full article on Seeking Alpha
Seeking Alpha • Feb 26

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Summary Exscientia's stock has been stagnant, with a 22% drop after the termination of its CEO due to inappropriate conduct. The company's pipeline efforts include CDK7 inhibitor GTAEXS617 and LSD1 inhibitor EXS74539, with clinical trials starting this year. Exscientia has entered into a collaboration with Sanofi, which could potentially bring in $45 million upfront and $300 million in milestones and royalties. Signals from the market, including shifts among institutional backers and a modest short interest, point to a guarded optimism, indicating potential hurdles in keeping up the momentum. In light of the amalgamation of breakthrough technology, solid financial health, yet mixed market sentiments, and recent executive upheaval, my recommendation shifts to "hold." Read the full article on Seeking Alpha
Analiz Makalesi • Jan 11

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Nov 12

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Exscientia plc ( NASDAQ:EXAI ) just released its latest third-quarter results and things are looking bullish. Revenue...
Analiz Makalesi • Aug 31

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Celebrations may be in order for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Analiz Makalesi • Aug 25

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Jul 21

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia plc ( NASDAQ:EXAI ) shareholders will have a reason to smile today, with the analysts making substantial...
Analiz Makalesi • Apr 22

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Dec 30

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Aug 31

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Today is shaping up negative for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 15

Exscientia: Using AI To Power Drug Development

Today, we take our first look at Exscientia, a unique developmental concern using artificial intelligence or AI to help identify promising drug compounds. Its platform has drawn numerous collaboration deals from the likes of Sanofi and Bristol-Myers Squibb. An investment analysis follows in the paragraphs below. It's not treason if you win. ― Lisa Shearin, Bewitched & Betrayed Today, we put Exscientia (EXAI) in the spotlight for the first time. The developmental biotech concern has a fairly unique method of drug discovery and is headquartered across the pond. The shares came public less than a year ago but are not in 'Busted IPO' territory. What lies ahead for Exscientia? An analysis follows below. Seeking Alpha Company Overview Exscientia is located in Oxford in the United Kingdom. The company is focused on developing small molecule drug candidates. Exscientia's AI developmental platform enables it to design candidate drug molecules, as well as to provide patients with drug therapies. The firms provides end-to-end solution of AI and technologies for target identification, drug candidate design, translational models, and patient selection. The stock currently trades under $13.00 a share and sport a market capitalization just under $1.6 billion. June Company Presentation The company is bringing together a team of industry scientists and technologists which are looking to streamline the drug discovery process by extensively using AI to design and develop better molecules. June Company Overview The company has numerous collaboration partners including Bristol-Myers Squibb Company (BMY), the Bill & Melinda Gates Foundation, and Sanofi (SNY), which came on board this year. June Company Presentation In fact, the new partnership with Sanofi is the biggest news around Exscientia so far in 2022. This agreement provides for the development of up to 15 novel small molecule candidates across oncology and immunology in early January. June Company Presentation The deal provided a $100 million upfront payment to Exscientia which it recorded in April. The company can also earn up to $5.2 billion in additional milestone payments as well sales royalties in the high-single-digits to mid-teens. The agreement also provides an option for clinical co-investment by Exscientia to increase the royalty rate up to 21% on net sales of co-funded products. As can be seen below, this is one of many collaboration deals the company has in place. June Company Presentation Analyst Commentary & Balance Sheet Despite a market cap north of one and a half billion dollars, the company gets little intention from Wall Street. Most likely because of an overseas domicile. On June 13th, Morgan Stanley maintained its Equal Weight rating on the stock and lowered its price target a buck a share to $20. A month prior, Goldman Sachs had reissued its Buy rating and $20 price target on EXAI. That is the only analyst ratings I can find on the stock so far in 2022. June Company Overview Just over two percent of the stock's outstanding float is currently held short. The company ended the second quarter with nearly $720 million in cash and marketable securities after posting a GAAP net loss of -£0.41 a share in the quarter. The company only burned through a bit over $10 million in cash to fund all operations during the last quarter. Verdict The current analyst consensus has the company losing 90 cents a share on $69 million in revenue in FY2022. In FY2023, losses are expected to increase to nearly $1.50 a shares as revenues fall. It should be noted, that few firms have projections on Exscientia's and there is a very wide range to earnings and revenue estimates. Given that all revenues in coming year will come from either developmental milestones within existing collaboration deals or upfront payments from new collaboration agreements, one can't blame analyst firms for having a very difficult time modeling future revenue streams. June Company Presentation The company has made some good progress in showing that its AI enabled platform can more effectively identify promising early stage drug candidates. This is a key reason it has garnered an impressive list of collaboration partners.
Analiz Makalesi • May 29

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:EXAI - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202661N/AN/AN/A1
12/31/202559N/AN/AN/A1
12/31/202439N/AN/AN/A1
9/30/202417-151-119-103N/A
6/30/202421-130-112-100N/A
3/31/202420-129-122-105N/A
12/31/202320-146-144-118N/A
9/30/202324-144-195-166N/A
6/30/202322-148-205-173N/A
3/31/202326-141-119-88N/A
12/31/202227-119-83-61N/A
9/30/202225-100-46-28N/A
6/30/202236-69317N/A
3/31/202229-59-23-13N/A
12/31/202127-49-14-7N/A
9/30/202127-36-70N/A
6/30/202110-39-15-11N/A
3/31/202113-24-31-27N/A
12/31/202010-22-24-21N/A
12/31/20199-657N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EXAI 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.6% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: EXAI 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: EXAI şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: EXAI şirketinin gelirinin (yıllık 39.8% ) US pazarından (yıllık 11.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EXAI şirketinin gelirinin (yıllık 39.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EXAI 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/11/22 13:47
Gün Sonu Hisse Fiyatı2024/11/19 00:00
Kazançlar2024/09/30
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Exscientia plc 3 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Alec StranahanBofA Global Research
Hiroshi ShibutaniGoldman Sachs
Brendan SmithTD Cowen